Polyrizon Ltd.(PLRZ)

Search documents
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
GlobeNewswire News Room· 2025-07-22 12:32
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for ...
Polyrizon Retains Nasdaq Listing Following Hearings Panel
Globenewswire· 2025-07-15 11:55
Core Viewpoint - Polyrizon Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market, following a plan to address concerns regarding its capital structure and compliance with listing standards [1][3]. Group 1: Nasdaq Listing and Compliance - The Nasdaq Listing Qualifications Department previously issued a public interest determination under Listing Rule 5101 due to the company's issuance of securities in a private placement, particularly concerning Series A warrants [2]. - A hearing was held on June 26, 2025, where Polyrizon presented its plan to avoid complex financing instruments in future capital-raising activities [3]. - The Panel's determination on July 9, 2025, allows the company to maintain its listing, contingent upon regaining compliance with the Minimum Bid Price Rule by October 17, 2025 [3]. Group 2: Financial Position and Capital Structure - Following the private placement, the company reported a cash balance of approximately $15.68 million, and all warrants issued in the transaction have been exercised, simplifying its capital structure [4]. - The elimination of a significant source of potential dilution is expected to enhance long-term shareholder value [4]. Group 3: Internal Controls and Future Plans - The company is implementing a formal internal control framework to govern future securities issuances and ensure compliance with Nasdaq standards, including enhanced oversight and quarterly internal compliance reviews [5]. Group 4: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [5]. - The proprietary Capture and Contain hydrogel technology is designed to function as a "biological mask," and the company is also developing the Trap and Target technology for nasal delivery of active pharmaceutical ingredients [5].
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Globenewswire· 2025-06-12 11:32
Core Insights - Polyrizon Ltd. announced positive preclinical results for its hydrogel-based Trap & Target (T&T) platform, indicating effective drug delivery to the upper nasal cavity, which is crucial for central nervous system (CNS) applications [1][4] Group 1: Study Results - The study, conducted with the University of Parma, showed that Polyrizon's hydrogel formulation achieved over 60% preferential accumulation in the middle and upper turbinates, enhancing nose-to-brain transport [3] - The results suggest potential applications for CNS indications, such as opioid overdose treatment and seizure management, where rapid brain access is critical [3][4] Group 2: Technology Validation - The CEO of Polyrizon emphasized the validation of the T&T technology's ability to achieve localized deposition in favorable nasal regions, which could lead to new therapies for acute neurological and psychiatric conditions [4] - The hydrogel demonstrated consistent delivery to upper nasal segments while maintaining favorable handling characteristics, supporting further preclinical development [4] Group 3: Future Plans - Polyrizon plans to validate these preclinical results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology [5]
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Globenewswire· 2025-05-23 20:15
Core Viewpoint - Polyrizon Ltd. has received a notification from Nasdaq regarding potential delisting due to shareholder dilution concerns related to a recent securities issuance [1][2] Group 1: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [3] - The company's proprietary technology, Capture and Contain (C&C), is designed to function as a "biological mask" and is delivered via nasal sprays [3] - Polyrizon is also developing Trap and Target (T&T) technology for the nasal delivery of active pharmaceutical ingredients, which is currently in pre-clinical development [3] Group 2: Nasdaq Notification Details - Nasdaq's Listing Qualifications Department has determined that the issuance of Series A warrants under a securities purchase agreement raises public interest concerns due to substantial dilution for shareholders [1] - The company has the option to request a hearing before a Hearings Panel to contest the delisting, which would stay any suspension or delisting actions pending the outcome of the hearing [2]
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Globenewswire· 2025-05-21 11:10
Core Insights - Polyrizon Ltd. has announced significant results from ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform [1][2][3] Group 1: Study Findings - The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, using excised rabbit nasal mucosa to simulate human nasal tissues [2] - Advanced ex vivo studies showed that Polyrizon's formulation spreads rapidly and uniformly across the nasal mucosa, forming a consistent surface layer [3] - Mucoadhesion testing indicated that the formulation maintains strong attachment to nasal tissue, even under conditions simulating physiological nasal fluid flow, supporting prolonged efficacy [3][4] Group 2: Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based barrier in the nasal cavity to protect against viruses and allergens [5] - The proprietary Capture and Contain (C&C) hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and prolonged retention for drug delivery [5] - An additional technology, Trap and Target (T&T), is in pre-clinical development focused on nasal delivery of active pharmaceutical ingredients [5]
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Globenewswire· 2025-05-13 11:45
Company Overview - Polyrizon Ltd. is a development stage biotech company focused on innovative intranasal hydrogels and has initiated preclinical studies for intranasal Benzodiazepines (BZDs) targeting acute repetitive seizures and status epilepticus [1][4] - The company utilizes its proprietary Trap and Target™ (T&T) platform for the intranasal administration of BZDs, aiming to provide rapid and patient-friendly seizure rescue therapy [4][6] Industry Context - According to the World Health Organization, epilepsy affects approximately 50 million people globally, with many existing therapies failing to adequately control acute repetitive seizures [2] - The global market for acute repetitive seizures was valued at USD 3.15 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2030 [2] Research Collaboration - The preclinical studies will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma, an expert in intranasal and pulmonary drug delivery solutions [3] Advantages of Intranasal Delivery - Intranasal delivery of BZDs offers several advantages over traditional administration routes, including ease of use and increased accessibility, allowing for rapid administration of life-saving medication in out-of-hospital settings [5]
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
Globenewswire· 2025-04-25 11:37
Core Viewpoint - Polyrizon Ltd. has announced a successful preliminary safety study for its PL-14 Allergy Blocker, marking a significant advancement in the product's development path [1][5]. Group 1: Study Details - The safety study was conducted on fully differentiated human nasal tissue using the MucilAir™ model, demonstrating strong local tolerability [2]. - The study assessed local tolerance and tissue response after a 4-hour application of PL-14, a mucoadhesive nasal gel spray designed to act as a physical barrier against airborne allergens [3]. - Key safety indicators evaluated included tissue integrity (TEER), cytotoxicity (LDH), cilia beating frequency (CBF), mucociliary clearance (MCC), and inflammatory response (IL-8 secretion), with results showing no signs of inflammatory activation or functional impairment [4]. Group 2: Regulatory and Development Plans - The results of the study are a milestone in validating the local safety of PL-14 and support the company's clinical development plans [5]. - The data will aid in the regulatory strategy and support an upcoming FDA pre-submission meeting, with U.S. and European clinical trials expected to begin in late 2025 or early 2026 [6]. Group 3: Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [7]. - The company is developing its proprietary Capture and Contain (C&C) hydrogel technology, which aims to enhance bioadhesion and prolonged retention for intranasal drug delivery [7].
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
Globenewswire· 2025-04-02 13:05
Core Insights - Polyrizon Ltd. has entered into a collaboration with a globally recognized branding and trademark consultancy to develop a strategic brand name and identity for its Capture and Contain™ hydrogel technology [1][2] - The Capture and Contain™ hydrogel technology is designed to create a protective biological barrier against allergens and viruses, marking a significant step in Polyrizon's commercialization efforts [2][4] - The engagement will include comprehensive trademark screening and linguistic evaluations in the U.S. and European markets to ensure brand viability and regulatory compliance [3] Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which form a barrier in the nasal cavity against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology consists of naturally occurring building blocks and functions as a "biological mask" [4] - Polyrizon is also developing additional technology, Trap and Target™, aimed at the nasal delivery of active pharmaceutical ingredients, which is currently in pre-clinical development [4]
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
Globenewswire· 2025-04-01 20:09
Core Viewpoint - Polyrizon Ltd. has successfully closed a private placement raising approximately $17.0 million through the sale of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit [1][3]. Group 1: Offering Details - The offering included the sale of 35,416,667 Ordinary Units, each comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant to purchase one Ordinary Share [2]. - The initial exercise price for each Series A Warrant is set at $1.20 per Ordinary Share, with a term of 30 months, and is subject to shareholder approval [2]. - The Pre-Funded Warrants can be exercised at any time following shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [6]. - The company's proprietary technology, Capture and Contain TM, aims to function as a "biological mask" and is being further developed for drug delivery [6]. - Polyrizon is also working on an earlier-stage technology, Trap and Target ™, for nasal delivery of active pharmaceutical ingredients [6].
Polyrizon Ltd. Announces $17.0 Million Private Placement
Globenewswire· 2025-03-31 13:32
Core Viewpoint - Polyrizon Ltd. has announced a definitive agreement for the sale of approximately $17.0 million in Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit, aimed at supporting its innovative intranasal hydrogel technology [1][3]. Group 1: Offering Details - The offering includes the sale of 35,416,667 Ordinary Units, each consisting of one Ordinary Share or Pre-Funded Warrant and one Series A Warrant to purchase one Ordinary Share per warrant [2]. - The initial exercise price of each Series A Warrant is set at $1.20 per Ordinary Share, with a term of 30 months, and will be exercisable following shareholder approval [2]. - The transaction is expected to close on or about April 1, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Polyrizon is a development-stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [6]. - The company's proprietary technology, Capture and Contain TM, aims to function as a "biological mask" in the nasal cavity [6]. - Polyrizon is also developing additional technology for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target ™ [6].